Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telemedicine | 2 | 2023 | 73 | 0.880 |
Why?
|
| Neurology | 2 | 2019 | 45 | 0.800 |
Why?
|
| Stroke | 7 | 2023 | 522 | 0.770 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2018 | 5 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 142 | 0.590 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2014 | 40 | 0.290 |
Why?
|
| Thrombolytic Therapy | 3 | 2014 | 59 | 0.270 |
Why?
|
| Fibrinolytic Agents | 3 | 2014 | 70 | 0.260 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2023 | 7 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2023 | 30 | 0.230 |
Why?
|
| Ischemic Attack, Transient | 1 | 2020 | 46 | 0.190 |
Why?
|
| Electroencephalography | 1 | 2018 | 71 | 0.160 |
Why?
|
| Aged | 6 | 2023 | 9461 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 863 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2014 | 14 | 0.130 |
Why?
|
| Teleradiology | 1 | 2013 | 1 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1216 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2013 | 136 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 666 | 0.100 |
Why?
|
| United States | 1 | 2019 | 3604 | 0.100 |
Why?
|
| Humans | 8 | 2023 | 28998 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 880 | 0.080 |
Why?
|
| Female | 4 | 2018 | 18112 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 724 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2023 | 3094 | 0.070 |
Why?
|
| Dendrites | 1 | 2004 | 15 | 0.060 |
Why?
|
| Glycine | 1 | 2004 | 25 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 24 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2023 | 10 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 248 | 0.060 |
Why?
|
| Perfusion | 1 | 2023 | 64 | 0.060 |
Why?
|
| Thrombectomy | 1 | 2023 | 58 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 3712 | 0.050 |
Why?
|
| Survivors | 1 | 2023 | 144 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2020 | 168 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 1362 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1997 | 0.040 |
Why?
|
| Risk Factors | 2 | 2013 | 3509 | 0.030 |
Why?
|
| Middle Aged | 3 | 2014 | 10805 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 3100 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2014 | 7 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 163 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2013 | 28 | 0.030 |
Why?
|
| California | 1 | 2013 | 60 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 85 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 96 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2012 | 1 | 0.030 |
Why?
|
| Telephone | 1 | 2013 | 48 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2013 | 190 | 0.030 |
Why?
|
| Physicians | 1 | 2014 | 134 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2012 | 62 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2013 | 210 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2013 | 113 | 0.030 |
Why?
|
| Male | 3 | 2014 | 17767 | 0.030 |
Why?
|
| Patient Selection | 1 | 2013 | 257 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2012 | 501 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 784 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1105 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 2010 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1300 | 0.020 |
Why?
|
| COP-Coated Vesicles | 1 | 2004 | 1 | 0.020 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2004 | 3 | 0.020 |
Why?
|
| Resorcinols | 1 | 2004 | 6 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 6 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 2004 | 15 | 0.020 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2004 | 6 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2004 | 14 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 15 | 0.020 |
Why?
|
| Protein Transport | 1 | 2004 | 74 | 0.020 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2004 | 23 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2004 | 36 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2004 | 256 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 799 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 747 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1604 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 7296 | 0.010 |
Why?
|